Price
No data yet.
Social Signal Score
Analyst Ratings
12 analystsRevenue
$7.67M-7.96%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- David L. Fischel
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Employees
- 131
- Beta
- 1.42
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -13.62
Financials
Revenue
$7.67M-8.0%Net Income
$-4.47MEBITDA
$-4.47MFree Cash Flow
$-3.74MEPS (diluted)
$-0.05Shares Outstanding (diluted)
100.03M+357.4%Operating Expenses
$9.05MCash & Debt
$10.49MReturn of Capital
$0.00Revenue by Segment (annual)
$32.38MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $32.38M | $-21.64M | $-0.25 |
| 2024 | $26.92M | $-24.05M | $-0.30 |
| 2023 | $26.77M | $-20.71M | $-0.27 |
| 2022 | $28.15M | $-18.29M | $-0.26 |
| 2021 | $35.02M | $-10.72M | $-0.16 |
| 2020 | $26.63M | $-6.65M | $-0.11 |
| 2019 | $28.90M | $-4.59M | $-0.07 |
| 2018 | $29.35M | $116.8K | $0.00 |
| 2017 | $31.14M | $-5.89M | $-0.26 |
| 2016 | $32.16M | $-5.29M | $-0.24 |
| 2015 | $37.67M | $-7.35M | $-0.35 |
| 2014 | $35.01M | $-5.20M | $-0.26 |
| 2013 | $38.03M | $-68.76M | $-5.95 |
| 2012 | $46.56M | $-9.24M | $-1.25 |
Valuation
STXShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
105Social Signal Score
Mentions (4)
- Newsseekingalpha.com·55d ago·Positive
Stereotaxis, Inc. (STXS) Q2 2026 Earnings Call Transcript Stereotaxis, Inc. (STXS) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·55d ago·Positive
Stereotaxis Q2 Earnings Call Highlights Stereotaxis NYSEAMERICAN: STXS reported second-quarter 2026 revenue of $7.7 million, as growth in sales of its robotic catheter portfolio helped lift recurring revenue to a multiyear high despite lower system revenue and continued supply constraints.
View source ↗ - Newszacks.com·55d ago·Negative
Stereotaxis Inc. (STXS) Reports Q2 Loss, Lags Revenue Estimates Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to a loss of $0.05 per share a year ago.
View source ↗ - Newsglobenewswire.com·55d ago·Neutral
Stereotaxis Reports 2026 Second Quarter Financial Results & Business Updates ST. LOUIS, Mo., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported business updates and financial results for the second quarter ended June 30, 2026.
View source ↗
Earnings
Tue, Nov 10(in 5 weeks)
Consensus estimate $-0.05 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 11$-0.05 vs $-0.05beat
- Tue, May 12$-0.03 vs $-0.04beat
- Mon, Mar 9$-0.06 vs $-0.06beat
- Tue, Nov 11$-0.03 vs $-0.06beat
- Thu, Aug 7$-0.05 vs $-0.07beat
- Mon, May 12$-0.07 vs $-0.07beat
Estimates and results for STXS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by STXS officers and directors.
- Bought
- $638k
- Sold
- —
42 trades
0 trades
- Isaac Paul Jbought
- Isaac Paul Jbought
- Isaac Paul Jbought
- Isaac Paul Jbought
- Isaac Paul Jbought
- Isaac Paul Jbought
- Isaac Paul Jbought
- Isaac Paul Jbought
58 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in STXS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.